Structural basis for inhibition promiscuity of dual specific thrombin and factor Xa blood coagulation inhibitors.Nar, H., Bauer, M., Schmid, A., Stassen, J.M., Wienen, W., Priepke, H.W., Kauffmann, I.K., Ries, U.J., Hauel, N.H.
(2001) Structure 9: 29-38
- PubMed: 11342132
- DOI: https://doi.org/10.1016/s0969-2126(00)00551-7
- Primary Citation of Related Structures:
1G2L, 1G2M, 1G30, 1G32, 1G36, 1OYQ
- PubMed Abstract:
A major current focus of pharmaceutical research is the development of selective inhibitors of the blood coagulation enzymes thrombin or factor Xa to be used as orally bioavailable anticoagulant drugs in thromboembolic disorders and in the prevention of venous and arterial thrombosis. Simultaneous direct inhibition of thrombin and factor Xa by synthetic proteinase inhibitors as a novel approach to antithrombotic therapy could result in potent anticoagulants with improved pharmacological properties.
Department of Medicinal Chemistry, Boehringer Ingelheim Pharma KG, 88397 Biberach an der Riss, Germany. firstname.lastname@example.org